Innovent Biologics, Inc. announced that the phase 2 clinical study of higher dose mazdutide in Chinese adults with obesity achieved the 24-week primary endpoint.
Innovent Biologics, Inc. announced that the phase 2 clinical study of higher dose mazdutide in Chinese adults with obesity achieved the 24-week primary endpoint.